Here, we extended the application of DR_MOMP to include the effect of ABT-199 on the apoptosis signalling network, and to determine whether the deterministic model could also be used as a stratification tool for the BCL-2 antagonist ABT-199 in in vivo CRC patient derived xenograft (PDX) models (Figure 1). The gene discussed is BCL2; the disease is colorectal carcinoma.